Artal Group S.A. Erasca, Inc. Transaction History
Artal Group S.A.
- $1.58 Billion
- Q2 2024
A detailed history of Artal Group S.A. transactions in Erasca, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 9,630,810 shares of ERAS stock, worth $26.3 Million. This represents 1.44% of its overall portfolio holdings.
Number of Shares
9,630,810
Previous 4,721,194
103.99%
Holding current value
$26.3 Million
Previous $9.73 Million
133.71%
% of portfolio
1.44%
Previous 0.52%
Shares
4 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$44.3 Million2.26% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$44.3 Million4.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$37.6 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$30.2 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$29 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $333M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...